Ramón
García Sanz
Profesor Titular de Universidad
Centre Hospitalier Regional et Universitaire de Lille
Lila, FranciaPublicaciones en colaboración con investigadores/as de Centre Hospitalier Regional et Universitaire de Lille (14)
2023
-
Diagnostics in Waldenström’s macroglobulinemia: a consensus statement of the European Consortium for Waldenström’s Macroglobulinemia
Leukemia, Vol. 37, Núm. 2, pp. 388-395
-
Plain Language Summary of the iNNOVATE study: ibrutinib plus rituximab is well-tolerated and effective in people with Waldenström's macroglobulinemia
Future Oncology, Vol. 19, Núm. 5, pp. 345-353
-
Report of Consensus Panel 3 from the 11th International workshop on Waldenström's Macroglobulinemia: Recommendations for molecular diagnosis in Waldenström's Macroglobulinemia
Seminars in Hematology
2022
-
Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenström's Macroglobulinemia: Final Analysis From the Randomized Phase III iNNOVATE Study
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 40, Núm. 1, pp. 52-62
2018
-
Phase 3 trial of Ibrutinib plus rituximab in Waldenstrom's macroglobulinemia
New England Journal of Medicine, Vol. 378, Núm. 25, pp. 2399-2410
2016
-
An international, multicenter, prospective, observational study of neutropenia in patients being treated with lenalidomide + dexamethasone for relapsed or relapsed/refractory multiple myeloma (RR-MM)
American Journal of Hematology, Vol. 91, Núm. 8, pp. 806-811
-
International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment
Journal of Clinical Oncology, Vol. 34, Núm. 13, pp. 1544-1557
2015
-
American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma
Biology of Blood and Marrow Transplantation, Vol. 21, Núm. 12, pp. 2039-2051
2014
-
Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensus
Blood, Vol. 124, Núm. 9, pp. 1404-1411
2013
-
International myeloma working group recommendations for the treatment of multiple myeloma-related bone disease
Journal of Clinical Oncology, Vol. 31, Núm. 18, pp. 2347-2357
-
Primary therapy of Waldenström macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): Long-term results of a phase 2 study of the European Myeloma Network (EMN)
Blood, Vol. 122, Núm. 19, pp. 3276-3282
-
Response assessment in Waldenström macroglobulinaemia: Update from the VIth International Workshop
British Journal of Haematology, Vol. 160, Núm. 2, pp. 171-176
2009
-
The use of bisphosphonates in multiple myeloma: Recommendations of an expert panel on behalf of the European Myeloma Network
Annals of Oncology, Vol. 20, Núm. 8, pp. 1303-1317